Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 96

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 96
---
 current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward -lookingstatements should not be relied upon as representing the views of NLS or Kadimastem as of any subsequent date, and neither NLS nor Kadimastem undertake any obligation to update forward -lookingstatements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward -lookingstatements in deciding how to grant your proxy or to instruct how your vote should be cast or how you should vote your shares on the proposals set forth in this proxy statement/prospectus. As a result of a number of known and unknown risks and uncertainties, the actual results or performance of NLS may be materially different from those expressed or implied by these forward -lookingstatements. Some factors that could cause actual results to differ include: •the occurrence of any event, change or other circumstances that could delay the Merger or give rise to the termination of the Merger Agreement; •the outcome of any legal proceedings that may be instituted against NLS or Kadimastem following announcement of the proposed Merger and transactions contemplated thereby; •the inability to complete the Merger due to the failure to obtain approval of the shareholders of NLS or to satisfy other conditions to the Closing in the Merger Agreement; •the ability to obtain or maintain the listing of NLS Common Shares on Nasdaq following the Merger; •the risk that the proposed Merger disrupts current plans and operations of NLS as a result of the announcement and consummation of the transactions described herein; •the ability to recognize the anticipated benefits of the Merger, which may be affected by, among other things, competition and the ability of NLS to grow and manage growth profitably; •costs related to the Merger; •changes in applicable laws or regulations; •the occurrence of one or more high profile accidents by autonomous driving vehicles that result in lower customer demand or more stringent regulations in one or more jurisdictions in which NLS intends to operate; •NLS’s ability to raise capital; •the possibility that NLS or Kadimastem may be adversely affected by other economic, business and/or competitive factors; •other risks and uncertainties described in this proxy statement/prospectus, including those under the section entitled “Risk Factors”; and •other factors beyond the control of NLS and Kadimastem